Newman Ferrara LLP Announces Corporate Governance Investigations of Zentalis Pharmaceuticals, Inc. (ZNTL)

newman-ferrara-llp-announces-corporate-governance-investigations-of-zentalis-pharmaceuticals,-inc.-(zntl)

NEW YORK–(BUSINESS WIRE)–$ZNTL #NYTop100–Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) (“Zentalis” or the “Company”). The investigations concern whether certain of the Zentalis’ officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of the Company’s business practices.

Current stockholders of Zentalis that seek more information on this matter are invited to contact Newman Ferrara attorneys Jeffrey Norton ([email protected]) or Benjamin Baker ([email protected]) to discuss this investigation and their rights.

Newman Ferrara maintains a multifaceted practice based in New York City with attorneys specializing in complex commercial and multi-party litigation, securities fraud and shareholder litigation, consumer protection, civil rights, and real estate. For more information, please visit the firm website at www.nfllp.com.

Contacts

Newman Ferrara LLP

Jeffrey M. Norton

[email protected]
1250 Broadway, 27th Fl.

New York, NY 10001

(212) 619-5400

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

For the last half century, thousands of communications professionals have turned to us to deliver their news to the audiences most important to their business through the sources they trust most. Over that time, we've gone from a single office with one full time employee to more than 500 employees in 32 bureaus.